Making Cancer Medicines With Microbes
For oncology, plant-based anti-cancer drugs have proven instrumental in the fight against a disease that claims approximately 609,360 lives in the United States alone. But their demand far outweighs their supply. Can yeast help?
Should #SciTwitter Migrate Elsewhere?
From tweets to toots – the online community #SciTwitter is considering a move from Twitter to an alternative online platform. In this article, we explore how Twitter has supported science communication and outreach over recent years, the motivations for migration and ask: where are you heading, #SciTwitter?
The Hunt for a Pan-Coronavirus Vaccine
Coronaviruses patently cause destructive pandemics, and it is possible that we will experience another one in our lifetimes. It makes sense to prepare a vaccine for possible future outbreaks, or for new variants of SARS-CoV-2, writes Anthony King.
The Pursuit of Global, Sustainable and Cooperative Open Science
Technology Networks had the pleasure of speaking with Nobel Laureate Elizabeth Blackburn on her impressive contributions to science and society. She highlights early inspirations that cemented her love of science, elaborates on the research that led to her being co-awarded the 2009 Nobel Prize in Physiology or Medicine, and explains why she is advocating for sustainable, cooperative and open science.
Closing the Vaccine Gap
Here, we explore some of the reasons behind vaccine hesitancy and highlight potential ways to combat the issue.
COVID-19 Childhood Vaccines: Why Don’t They Last a Lifetime, Like the Measles Shot?
Sophie Prosolek explores why some vaccines last a lifetime, while others do not, for Technology Networks.
Designing Vaccines With Reverse Vaccinology
Most vaccine development begins with looking at the pathogen. Scientists pinpoint key residues needed for the virus to enter the body and develop vaccines that train the body to recognize signatures of the foreign invader. Kevin O'Neil Saunders, associate professor of surgery and director of research at the Duke Human Vaccine Institute at Duke University develops vaccines after analyzing the body’s immune response to a pathogen.
The Omicron Variant Highlights the Need for Smarter, Future-Proof Vaccine Design
Investment in vaccine science and technology development can provide us with the tools to respond to pathogens with pandemic potential. In this opinion article, Ariana Gomes discusses the use of AI for creating universal vaccines.
Vaccines: Just Add Water
Cold-chain distribution requirements complicate vaccine access, reducing vaccination rates for life-threatening, but preventable diseases. Now, researchers have developed a portable production platform for shelf-stable, antibacterial vaccines.
A Next-Generation SARS-CoV-2 Vaccine
A naturally occurring nanoparticle yields a new type of vaccine that offers broad-acting protection against emerging SARS-CoV-2 variants. With further development, the approach may lead to a pan-coronavirus vaccine.
Progress Towards a Mucosal Vaccine for Pneumonia
In a new study, researchers describe a subunit mucosal vaccine that induces broadly protective immunity against Klebsiella pneumoniae strains. Technology Networks interviewed author Jay Kolls to learn more about the findings and their significance.
Nanoparticles – Enabling Innovation in Vaccine Design
Nanoparticle-based vaccines have emerged as a potential alternative to conventional and subunit vaccines. This article explores the various properties and advantages of nanoparticles which allow the design of vaccines with enhanced antigen presentation and strong immunogenicity.